Home > Search Results: Kher, U.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
11 p, 588.4 KB Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma : results from the randomised phase III KEYNOTE-062 study / Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Valderrama, A. (Center for Observational and Real-World Evidence, Merck) ; Bang, Yung-Jue (Seoul National University College of Medicine) ; Fuchs, C. S. (Yale University Cancer Center) ; Shitara, Kohei (National Cancer Center Hospital East, Kashiwa, Japan) ; Janjigian, Y. Y. (Memorial Sloan Kettering Cancer Center) ; Qin, S. (PLA Cancer Centre of Nanjing Bayi Hospital) ; Larson, T. G. (Minnesota Oncology Hematology) ; Shankaran, V. (Seattle Cancer Care Alliance) ; Stein, S. (Yale University Cancer Center) ; Norquist, J. M. (Center for Observational and Real-World Evidence, Merck) ; Kher, U. (Department of Medical Oncology, Merck) ; Shah, S. (Department of Medical Oncology, Merck) ; Alsina, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. [...]
2021 - 10.1016/j.esmoop.2021.100189
ESMO open, Vol. 6 (august 2021)  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with